ADA Scientific Sessions 2026 Preview: 6 Trials to Know

The American Diabetes Association (ADA) 2026 Scientific Sessions are set to begin on Friday, June 5th, in New Orleans, Louisiana. The core of this year’s conference is the myriad GLP-1 therapies that have made substantial strides over recent months. The groundbreaking triple agonist retatrutide will be accompanied by CagriSema, survodutide, and elecoglipron as investigators showcase their efficacy in patients with diabetes and obesity.